Skip to content
Review Open access

Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 223 references
Medicine

TL;DR

By illustrating how specific autoantibody–autoantigen axes may translate systemic autoimmunity into restricted clinical patterns, this framework provides a unifying model for disease heterogeneity and supports the development of precision, antigen-targeted therapeutic strategies.

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a remarkably broad and heterogeneous autoantigen repertoire. While epitope spreading, aberrant B-cell activation, and molecular mimicry act in concert with defective apoptotic clearance and sustained type I interferon signaling to drive systemic autoreactivity, many clinical manifestations of the disease are highly localized. The involvement of neuropsychiatric, renal, cutaneous, pulmonary, vascular, and hepatic systems appears to be shaped by tissue-specific autoantigen exposure and local microenvironments, where shared immunopathogenic pathways give rise to organ-associated autoantigenic landscapes. This review develops the concept of organ-associated autoantigenic landscapes, defined here as context-dependent configurations in which autoantibody–autoantigen interactions intersect with regional microenvironments and may contribute to inflammatory cascades, complement activation, and cellular damage. Importantly, organ association does not imply strict organ specificity, as the same circulating autoantibody may acquire distinct clinical relevance across tissues depending on antigen accessibility and local effector conditions. By illustrating how specific autoantibody–autoantigen axes may translate systemic autoimmunity into restricted clinical patterns, this framework provides a unifying model for disease heterogeneity and supports the development of precision, antigen-targeted therapeutic strategies.

Read PDF

Similar papers

Review Sep 2026

Autoimmune diseases: distinct disorders or diverse manifestations of a common pathogenic process?

Autoimmune diseases arise from the amplification of natural autoreactive immune clones in genetically susceptible individuals under the influence of environmental triggers, epigenetic modifications, and hormonal factors. They comprise a broad and heterogeneous group of disorders characterized by immune-mediated tissue...

H. Moutsopoulos · 0 citations
Review Oct 2026

Long-lived plasma cells in rheumatic and selected antibody-mediated autoimmune diseases: biology, evidence, and therapeutic opportunities.

Persistent autoantibody production after conventional immunosuppression or B-cell depletion has focused attention on antibody-secreting cells that survive without ongoing proliferation. Long-lived plasma cells (LLPCs) are indispensable for durable protective immunity, but autoreactive members of this compartment may al...

Hong-Hao Guo, Wang Xiang, Liu-Ting Zeng et al. · 0 citations
Review Open access Oct 2026

CD40-CD40L interactions in systemic autoimmune diseases.

Systemic autoimmune diseases arise from a heterogeneous interplay of genetic, epigenetic, and environmental factors that culminates in loss of tolerance, chronic inflammation, and tissue injury. Among the pathways linking susceptibility to effector disease, CD40-CD40L is a central regulator of antigen presentation, T-B...

M. Hashimoto, M. Katsushima, F. Mackay et al. · 0 citations
Review Open access Oct 2026

Eosinophils in autoimmune diseases: context-dependent pathogenesis, functional heterogeneity, and therapeutic translation

Eosinophils are best known for their host defence against helminths and for their effector role in type 2 inflammation, but an expanding evidence base indicates that their functions extend to immune regulation, tissue repair, fibrosis, and selected autoimmune phenotypes. This narrative review critically evaluates eosin...

Zhi-Dan Fan, Wen-Jing Zhu, N. Huang et al. · 0 citations
Review Sep 2026

Regulated cell death in autoimmune diseases: molecular mechanisms and therapeutic opportunities

Improved understanding of the integrated landscape of the RCD network may facilitate the discovery of novel biomarkers and support the development of innovative therapies to restore immune tolerance and control chronic inflammatory damage in autoimmune diseases.

Zahra Taheri, Z. Zarei-Behjani, Gholamreza Daryabor et al. · 0 citations
Review Open access Oct 2026

Joint disease in systemic lupus erythematosus: clinical manifestations, immunopathology, and treatment

Joint involvement affects the majority of patients with systemic lupus erythematosus and is consistently ranked among the manifestations with the largest impact on daily function, yet lupus synovium remains one of the least interrogated major target tissues in this disease. The primary literature on lupus synovial ti...

Melissa Ong, F. Tariq, Arthi Mahto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.